Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it has acted as Financial PR & Investor Relations advisor for the AIM IPO of Spectral MD Holdings, Ltd. (AIM: “SMD”),
a predictive analytics group that develops proprietary AI algorithms and optical technology for faster treatment decisions in wound care. The team at Walbrook will now manage the Company’s communications with the financial media, research
analysts and non-institutional investors, including new and existing private investors.
On admission, Spectral MD Holdings, Ltd. completed a successful placing for gross proceeds of £11.3 million, with a market capitalisation of approximately £80 million.
Using its DeepView® Wound Imaging Solution, an internally developed AI technology and multispectral imaging system which has designated FDA Breakthrough Device, the Group is able to distinguish between damaged and healthy human tissue invisible to
the naked eye, providing 'Day One' healing assessments for burn wounds and diabetic foot ulcers ('DFU').
The Group has to date received substantial support from the US government with contracts from institutions such as Biomedical Advanced Research and Development Authority (BARDA), National Science Foundation (NSF), National Institute of Health (NIH) and
Defense Health Agency (DHA) in support of the burns application for its DeepView® system.
Paul McManus, Founder and Managing Director of Walbrook PR, commented: “We are delighted to work with Spectral MD and congratulate the company on their AIM IPO today. The Company’s ground-breaking technology has already received c. $100m in non-dilutive funding to develop it for the burn indication and IPO proceeds will now help improve DeepView® for DFU.
“We look forward to developing the Company’s profile with analysts, investors and journalists as they begin this exciting new chapter.”
For more information visit the Company’s website: https://www.spectralmd.com/
For further information please contact:
About Walbrook PR:
Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.
Walbrook PR advises more healthcare companies listed on the London Stock Exchange than any other company and is ranked #2 by number of AIM listed companies with 50 AIM listed clients (Source: AIM Advisers Rankings Guide, October 2021) and ranked #7 by total number of stock market listed clients (Corporate Advisers Rankings Guide, August 2021) advising a total of 58 stock market listed companies across a wide mix of sectors.
Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business.